FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL									
l	OMB Number:	3235-0287								
l	Estimated average burden									
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person* RTW INVESTMENTS, LP						2. Issuer Name and Ticker or Trading Symbol Milestone Pharmaceuticals Inc. [MIST]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)						
(Last) (First) (Middle) 40 10TH AVENUE, FLOOR 7						3. Date of Earliest Transaction (Month/Day/Year) 10/27/2020													
(Street) NEW YORK NY 10014					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting							
(City) (State) (Zip)														Person					
		Та	ble I - Non-D	erivat	ive S	ecurities	s Ac	quired, I	Disp	osed c	of, or Be	nefic	cially	Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ate	Execution Date,		Code (li	Transaction Disposed Code (Instr.		rities Acquired (A) or d Of (D) (Instr. 3, 4 a				s lly ollowing	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	V	Amount	(A) o (D)	r Pı	rice	Transaction(s) (Instr. 3 and 4)				(1130.4)	
			Table II - De (e.					uired, Di , option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Ir		n Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Derivative Security		9. Number derivative Securitie Beneficia Owned Following Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amor or Numl of Sh	ber		Transacti (Instr. 4)	ion(s)	n(s)		
Pre- Funded Warrant ⁽²⁾	\$0.01	10/27/2020		P		952,380		10/27/2020	D	(3)	Common Stock	952	,380	\$5.24	7,607,5	511	I	By RTW ⁽¹⁾	
		Reporting Person* IENTS, LP																	
(Last) (First) (Middle) 40 10TH AVENUE, FLOOR 7																			
(Street) NEW YORK NY 10			10014																
(City) (State) (Zip)																			
	nd Address of RODEF	Reporting Person*																	
(Last) (First) (Middle) C/O RTW INVESTMENTS, LP 40 10TH AVENUE, FLOOR 7																			
	AVENUE,	PLOUK /																	
(Street) NEW YORK NY 10014																			
(City)		(State)	(Zip)																

Explanation of Responses:

- 1. The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.
- 2. Each pre-funded warrant represents the right to acquire one share of common stock for an exercise price of \$0.01 per share. The ability of the holder to exercise the pre-funded warrant is subject to a beneficial ownership limitation initially set at 9.99% of the Company's issued and outstanding common stock. This beneficial ownership limitation may be increased or decreased at the election of the warrant holder, provided that any increase shall not be effective until the 61st day after notice of adjustment is provided to the Company.
- 3. The warrants do not have an expiration date

RTW Investments, LP; By: /s/ attorney-in-fact for RTW Investments, LP /s/ Alice Lee, attorney-in-fact

10/29/2020

Date

10/29/2020

for Roderick Wong

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.